<DOC>
	<DOCNO>NCT00106574</DOCNO>
	<brief_summary>This 2 arm study compare safety efficacy , regard reduction sign symptom , tocilizumab versus placebo combination traditional Disease-Modifying Anti-Rheumatic Drug ( DMARD ) therapy patient moderate severe active rheumatoid arthritis ( RA ) inadequate response current DMARD therapy . Patients randomize receive tocilizumab 8mg/kg iv placebo iv every 4 week , conjunction stable DMARD therapy . The anticipated time study treatment 3-12 month , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Assess Effect Tocilizumab + DMARD Therapy Signs Symptoms Patients With Moderate Severe Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<criteria>patient least 18 year age moderate severe active RA least 6 month ; inadequate response current antirheumatic therapy , include 1 traditional DMARDs ; stable DMARD therapy least 8 week enter study ; patient reproductive potential must use reliable method contraception . major surgery ( include joint surgery ) within 8 week enter study , plan surgery within 6 month enter study ; patient previously fail treatment antitumor necrosis factor agent ; woman pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>